TY - JOUR
TI - INSIGHT MM: A large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
AU - Costello, C.
AU - Davies, F.E.
AU - Cook, G.
AU - Vela-Ojeda, J.
AU - Omel, J.
AU - Rifkin, R.M.
AU - Berdeja, J.
AU - Puig, N.
AU - Usmani, S.Z.
AU - Weisel, K.
AU - Zonder, J.A.
AU - Terpos, E.
AU - Spencer, A.
AU - Leleu, X.
AU - Boccadoro, M.
AU - Thompson, M.A.
AU - Romanus, D.
AU - Stull, D.M.
AU - Hungria, V.
JO - Future Oncology
PY - 2019
VL - 15
TODO - 13
SP - 1411-1428
PB - Future Medicine Ltd
SN - 1479-6694, 1744-8301
TODO - 10.2217/fon-2019-0013
TODO - antineoplastic agent;  antineoplastic agent, Article;  cancer chemotherapy;  clinical feature;  clinical trial (topic);  health care utilization;  human;  multiple myeloma;  outcome assessment;  overall survival;  patient safety;  priority journal;  progression free survival;  quality of life;  treatment duration;  treatment response;  adolescent;  adult;  aged;  disease exacerbation;  follow up;  international cooperation;  middle aged;  multiple myeloma;  pathology;  prospective study;  quality of life;  treatment outcome;  tumor recurrence;  very elderly;  young adult, Adolescent;  Adult;  Aged;  Aged, 80 and over;  Antineoplastic Combined Chemotherapy Protocols;  Disease Progression;  Follow-Up Studies;  Humans;  International Agencies;  Middle Aged;  Multiple Myeloma;  Neoplasm Recurrence, Local;  Prospective Studies;  Quality of Life;  Treatment Outcome;  Young Adult
TODO - With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM) patients' outcomes have improved. However, the efficacy seen in clinical trials is often not seen in real-world settings and data on the effectiveness of MM therapies are needed. INSIGHT MM is a prospective, global, non-interventional, observational study that is enrolling approximately 4200 patients with newly diagnosed or relapsed/refractory MM, making it the largest study of its kind to date. The study aims to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapies chosen, clinical outcomes (response, treatment duration, time-to-next-therapy, progression-free and overall survival), safety, healthcare resource utilization and quality of life. One interim analysis has been conducted to date; current accrual is approximately 3094 patients. © 2019 Future Medicine Ltd.
ER -